Organization Profile

You just read:

OncoGenex Announces Initiation of Randomized Phase 2 "PACIFIC" Study of OGX-427 in combination with Zytiga® in Men with Metastatic Castrate-Resistant Prostate Cancer

News provided by

OncoGenex Pharmaceuticals, Inc.

Dec 19, 2012, 09:31 ET